Objectives To evaluate effect of duration of clopidogrel use on clinical outcomes in patients with coronary artery disease receiving drug-eluting stents (DES).
Methods A total of 426 patients with coronary artery disease receiving drug-eluting stents were enrolled. All patients were divided into two groups [12 months group (n = 262) and >12 months group (n = 164)] by duration of clopidogrel use. Baseline characteristics [age, gender, angiographic characteristics, 1eft ventricular ejection fraction (LVEF), history of hypertension, diabetes, hyperlipidemia, obesity and smoking] of two groups were collected. Major adverse cardiac events (MACE) including all-cause mortality, nonfatal myocardial infarction (MI), and stroke] were compared between the 12-month clopidogrel use group and the >12-month clopidogrel use group.
Results The average follow-up was 26.6 ± 7.5 months. Rates of male, history of smoking, obesity, hypertension and hyperlipidemia were not different between the two groups (P>0.05). Average LVEF and average age were significantly higher in the 12 months group than that of the >12 months group (P<0.05). Rate of diabetes was significantly lower in the 12 months group than that of the >12 months group (P<0.01). Incidence of MACE in follow-up period did not differ significantly between the 12 months group and the >12 months group (7.2% vs 4.9%, P>0.05).
Conclusions >12-month clopidogrel use in patients who had received DES was not significantly more effective than 12-month clopidogrel use in reducing the rate of death, MI and stroke.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.